



■ TEL. : 022 - 3001 5666
■ FAX : 022 - 2405 7708
■ E-Mail : info@naxparlab.com
■ Visit us at: www.naxparlab.com
■ CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

Date: 14.11.2019

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001

Sub: Submission of Un-Audited Standalone Financial Results for quarter and half year ended 30th September, 2019 in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Ref.: Parnax Lab Limited, Script Code- 506128

Dear Sir,

Kindly find enclosed herewith the following:

1. A Copy of Standalone & Consolidated Un-Audited Financial results with Limited Review Report of the Company for the quarter and half year ended 30th September, 2019;

Kindly take on record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

For PARNAX LAB LIMITED

PRAKASH SHAH
DIRECTOR
DIN: 00440980
Encl: As above

LADHA SINGHAL & ASSOCIATES
CHARTERED ACCOUNTANTS

To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8,
Jogani Industrial Complex,
Chunabhatti, Mumbai - 400 022

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Parnax Lab Limited** ("the company") for the quarter and six months ended September 30, 2019 together with the relevant notes thereon ("the Statement"). The Statement being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates

Chartered Accountants
(FRN: 120241W)

Vinod Ladha
(Vinod Ladha)
Partner
M. No. : 104151
Place : Mumbai
Dated : 14th November, 2019




LADHA SINGHAL & ASSOCIATES
CHARTERED ACCOUNTANTS

To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8, Jogani Industrial Complex,
Chunabhatti, Mumbai - 400 022

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Parnax Lab Limited** ("the Parent") and **Naxpar Pharma Private Limited** ("the Subsidiary") (the Parent and its subsidiary together referred to as "the Group") for the quarter and six months ended September 30, 2019 together with the relevant notes thereon ("the Statement"). The Statement submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
 2. The Statement is the responsibility of the Parent's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
 3. We conducted our review of the Statement in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- We also performed procedures in accordance with the circular issued by the SEBI under regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended, to the extent applicable.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Ladha Singhal and Associates**
Chartered Accountants
(FRN: 120241W)


(**Vinod Ladha**)
Partner
M. No. : 104151
Place : Mumbai
Dated : 14th November, 2019



PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2019


S. No.	Particulars	(Rs. in Lakhs)					
		Unaudited Current Quarter Ended 30.09.2019	Unaudited Previous Quarter ended 30.06.2019	Unaudited Correspondi ng Quarter Ended 30.09.2018	Unaudited Current Half Year Ended 30.09.2019	Unaudited Correspondi ng Half Year Ended 30.09.2018	Audited Year Ended 31.03.2019
I	Revenue from Operations	178.09	146.03	196.51	324.12	369.13	649.26
II	Other Income	7.06	7.25	19.66	14.31	24.82	51.21
III	Total Revenue (I+II)	185.15	153.28	216.17	338.43	393.95	700.47
IV	Expenses						
	a) Cost of Material Consumed	52.96	50.25	78.25	103.21	137.97	235.34
	b) Purchase of Stock in trade	55.21	34.06	23.30	89.27	52.42	83.09
	c) Changes in inventories of finished goods, Work in progress and stock in trade		-	-		-	-
	d) Employee benefit expenses	12.62	11.84	11.19	24.46	21.13	45.09
	e) Finance Costs	70.41	24.79	25.41	95.20	53.55	107.96
	f) Depreciation and amortisation expenses	1.10	1.09	1.18	2.20	2.43	4.84
	g) Other expenses	51.11	43.61	78.09	94.71	139.21	274.99
	h) Impairment of assets classified as held for disposal		-	-		-	-
	Total Expenses (IV)	243.41	165.64	217.42	409.05	406.71	751.31
V	Profit/(loss) before exceptional items and tax (III-IV)	(58.26)	(12.36)	(1.25)	(70.62)	(12.76)	(50.84)
VI	Exceptional Items		-	-		-	-
VII	Profit/(loss) Before Tax (V-VI)	(58.26)	(12.36)	(1.25)	(70.62)	(12.76)	(50.84)
VIII	Tax expense						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	31.90
	c) Short(Excess) Prov for Tax for Earlier Years	-	-	-	-	-	-
IX	Profit/ (Loss) for the period (VII-VIII)	(58.26)	(12.36)	(1.25)	(70.62)	(12.76)	(82.74)
X	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	(0.02)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XI	Total Other Comprehensive Income for the period	-	-	-	-	-	(0.02)
XII	Total Comprehensive Income comprising profit & other comprehensive income for the period (IX+XI)	(58.26)	(12.36)	(1.25)	(70.62)	(12.76)	(82.76)
XIII	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49	850.49	850.49
XIV	Earning per equity share (Not Annualised)						
	(1) Basic	(0.69)	(0.15)	(0.01)	(0.83)	(0.15)	(0.97)
	(2) Diluted	(0.69)	(0.15)	(0.01)	(0.83)	(0.15)	(0.97)



Notes-

1	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 14, 2019
2	The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and half year ended September 30, 2019
3	EPS for quarter ended is on non annualised basis.
4	The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
5	Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

By Order of the Board
For Parnax Lab Limited



Place : Mumbai

Date : 14-11-2019

Prakash M Shah
Whole Time Director & CEO
DIN : 00440980



PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN:-L36912MH1982PLC027925


Statement of Assets and Liabilities as at 30.09.2019

(Rs. in Lakhs)

S. No.	Particulars	Standalone		
		Unaudited 30.09.2019	Unaudited 30.09.2018	Audited 31.03.2019
A	ASSETS			
1	Non-Current Assets			
(a)	Property, plant and equipment	55.21	59.73	57.41
(b)	Capital work-in-progress		-	-
(c)	Investment in Subsidiaries	998.00	998.00	998.00
(d)	Goodwill		-	-
(e)	Other Intangible assets	0.06	0.15	0.06
(f)	Intangible assets under development		-	-
(g)	Biological Assets other than bearer plants		-	-
(h)	Financial assets			
(i)	Investments	8.95	8.95	8.95
(ii)	Trade Receivables		-	-
(iii)	Loans		-	-
(iv)	Other non-current financial assets	5.34	5.44	5.34
(i)	Deferred tax assets (net)	259.39	291.29	259.39
(j)	Advance income tax (net)		-	-
(k)	Other non-current assets		-	-
2	Current Assets			
(a)	Inventories	22.08	31.67	41.77
(b)	Financial assets			
(i)	Investments		-	-
(ii)	Trade Receivables	191.79	348.23	250.34
(iii)	Cash and cash equivalents	20.17	4.61	(52.99)
(iv)	Bank balances other than above	1.11	1.04	1.11
(v)	Loans	2.59	2.33	2.64
(vi)	Others financial assets		-	-
(c)	Current tax assets (Net)	13.29	14.79	14.79
(d)	Other current assets	83.58	108.94	81.30
(e)	Assets classified as held for sale	372.73	380.27	372.73
	TOTAL - ASSETS	2,034.29	2,255.44	2,040.84
B	EQUITY AND LIABILITIES			
1	Equity			
(a)	Equity share capital	850.49	850.49	850.49
(b)	Other equity	(138.65)	1.97	(68.04)
2	Liabilities			
(I)	Non-current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	267.04	845.76	833.31
(ii)	Trade Payables		-	-
(iii)	Other financial liabilities		-	-
(b)	Provisions	1.27	1.33	1.27
(c)	Deferred tax liabilities (Net)		-	-
(d)	Other non - current liabilities		-	-
(II)	Current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	779.15	194.33	226.70
(ii)	Trade payables	156.00	229.38	87.34
(iii)	Other current financial liabilities	105.00	92.77	108.00
(b)	Other current liabilities	13.83	39.24	1.61
(c)	Short-term provisions	0.16	0.17	0.16
(d)	Current tax liabilities (net)		-	-
	TOTAL EQUITY AND LIABILITIES	2,034.29	2,255.44	2,040.84

By Order of the Board
For Parnax Lab Limited

Prakash M Shah
Whole Time Director & CEO
DIN : 00440980



Mumbai
Date : 14-11-2019

PARNAX LAB LIMITED
Unaudited Standalone Cash Flow Statement

(Rs. in Lakhs)

Particulars	For the period ended 30th September 2019	For the year ended 31st March 2019
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit/(Loss) before tax	(70.62)	(50.84)
Adjustments for	-	-
Depreciation	2.20	4.84
Finance Cost	95.20	107.96
Loss on sale of Property, plant & equipments	-	-
Sundry Balances written off	0.40	6.35
Diminution in value of Investments	-	-
Impairment of assets classified as held for disposal	-	-
Interest & Dividend income	(0.09)	(0.07)
Operating Loss Before Working Capital Adjustments	27.09	68.24
Changes in Working Capital		
<u>Adjustments for (increase) / decrease in operating assets:</u>		
Inventories	19.69	(1.08)
Trade receivables	58.55	154.08
Other assets (Financials and Non Financial assets)	(2.64)	15.25
<u>Adjustments for increase / (decrease) in operating liabilities:</u>	-	-
Trade payables	68.65	(41.98)
Other liabilities (Financials and Non Financial assets)	9.23	(33.69)
Cash generated from operations	180.57	160.83
Direct Tax Paid (Refund) [Net]	(1.50)	(7.01)
Net cash flow from / (used in) operating activities (A)	182.07	167.84
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant & equipment		
Proceeds from sale of fixed assets	-	7.54
Proceeds/(Purchase) from sale of Non Current Investments	-	(4.90)
Interest & Dividend income	0.09	0.07
Net cash flow from / (used in) investing activities (B)	0.09	2.71
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from borrowings (net)	(74.31)	(171.80)
Finance Cost	(34.69)	(53.59)
Net cash flow from / (used in) financing activities (C)	(109.00)	(225.40)
Net increase (decrease) in cash and cash equivalents (A+B+C)	73.16	(54.85)
Cash and cash equivalents at the beginning of the year	(52.99)	1.86
Cash and cash equivalents at the end of the year	20.17	(52.99)



By Order of the Board
For Parnax Lab Limited

Prakash M Shah

Prakash M Shah
Whole Time Director & CEO
DIN : 00440980

Mumbai
Date : 14-11-2019

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN-L36912MH1982PLC027925

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30.09.2019

S. No.	Particulars	(Rs. in Lakhs)					
		Unaudited Current Quarter Ended 30.09.2019	Unaudited Previous Quarter ended 30.06.2019	Unaudited Corresponding Quarter Ended 30.09.2018	Unaudited Current Half Year Ended 30.09.2019	Unaudited Corresponding Half Year Ended 30.09.2018	Audited Current Year Ended 31.03.2019
I	Revenue from Operations	2,570.39	2,066.35	4,226.84	4,636.74	6,533.24	10,878.00
II	Other Income	9.04	7.50	84.16	16.54	90.51	211.02
III	Total Revenue (I+II)	2,579.43	2,073.85	4,311.00	4,653.28	6,623.75	11,089.02
IV	Expenses						
	a) Cost of Material Consumed	1,174.57	899.11	1,135.94	2,073.68	2,292.83	4,391.98
	b) Purchase of Stock in trade	78.36	7.02	729.16	85.38	771.30	901.57
	c) Changes in inventories of finished goods, Work in progress and stock in trade	-38.85	38.85	107.46	-	37.48	(22.08)
	d) Employee benefits expenses	335.85	357.89	372.29	693.74	670.23	1,306.04
	e) Finance Cost	138.37	101.49	87.32	239.86	179.13	388.76
	f) Depreciation and amortisation expenses	107.30	105.67	96.34	212.97	183.65	382.35
	g) Other expenses	747.96	556.50	1,366.29	1,304.46	2,000.87	3,278.41
	h) Impairment of assets classified as held for disposal	-	-	-	-	-	-
	Total Expenses (IV)	2,543.56	2,066.53	3,894.80	4,610.09	6,135.49	10,627.03
V	Profit/(loss) before exceptional items and tax (III-IV)	35.87	7.32	416.20	43.19	488.26	461.99
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	35.87	7.32	416.20	43.19	488.26	461.99
VIII	Tax expense						
	a) Current Tax	-	-	-	-	-	120.00
	b) Deferred Tax	-	-	-	-	-	6.74
	c) Short (Excess) Prov for Tax for Earlier Years	-	-	-	(4.40)	-	4.71
IX	Profit/ (Loss) for the period (VII-VIII)	35.87	7.32	416.20	47.59	488.26	330.54
X	Minority Interest Profit (Loss)	0.20	0.04	0.80	0.24	1.00	0.66
XI	Profit/(Loss) After Share of Profit (Loss) of minority interest	35.67	7.28	415.40	47.35	487.26	329.88
XII	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	(8.00)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XIII	Total Other Comprehensive Income for the period	-	-	-	-	-	(8.00)
XIV	Total Comprehensive Income comprising profit and other comprehensive income for the period (IX+XIII)	35.67	7.28	415.40	47.35	487.26	321.88
XV	Total profit/(loss) for the year attributable to:						
	- Owners of the Company	35.67	7.28	415.40	47.35	487.26	329.88
	- Non-controlling interests	0.20	0.04	0.80	0.24	1.00	0.66
XVI	Other Comprehensive income attributable to:						
	- Owners of the Company	-	-	-	-	-	(7.98)
	- Non-controlling interests	-	-	-	-	-	(0.02)
XVII	Total Comprehensive income attributable to:						
	- Owners of the Company	35.67	7.28	415.40	47.35	487.26	321.90
	- Non-controlling interests	0.20	0.04	0.80	0.24	1.00	0.64
XVIII	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49	850.49	850.49
XIX	Earning per equity share (Not Annualised)						
	(1) Basic	0.42	0.09	4.89	0.56	5.74	3.89
	(2) Diluted	0.42	0.09	4.89	0.56	5.74	3.89

Notes-

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 14, 2019
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and half year ended September 30, 2019
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

Place : Mumbai
Date : 14-11-2019

By Order of the Board
For Parnax Lab Limited

(Signature)
Prakash M Shah
Whole Time Director & CEO
DIN : 00440980



PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN:-L36912MH1982PLC027925

Statement of Consolidated Assets and Liabilities as at 30.09.2019

(Rs. in Lakhs)

S. No.	Particulars	Consolidated		
		Unaudited 30.09.2019	Unaudited 30.09.2018	Audited 31.03.2019
A	ASSETS			
1	Non-Current Assets			
(a)	Property, plant and equipment	4,899.24	4,396.82	5,078.32
(b)	Capital work-in-progress	238.58	272.22	14.15
(c)	Investment Property		-	-
(d)	Other Intangible assets	23.91	21.83	27.23
(e)	Financial assets			
(i)	Investments	21.46	28.22	21.46
(ii)	Other non-current financial assets	43.04	39.95	41.38
(f)	Deferred tax assets (net)		-	-
(g)	Other non-current assets	5.00	667.28	596.00
2	Current Assets			
(a)	Inventories	977.24	689.55	847.03
(b)	Financial assets			
(i)	Investments		-	-
(ii)	Trade Receivables	2,082.39	2,136.05	1,918.42
(iii)	Cash and cash equivalents	18.09	37.52	(5.19)
(iv)	Bank balances other than above	84.68	121.75	64.73
(v)	Loans	76.69	66.57	65.22
(c)	Current tax assets (Net)	148.76	110.29	86.10
(d)	Other current assets	253.32	409.09	340.47
(e)	Assets classified as held for sale	372.73	380.27	372.73
	TOTAL - ASSETS	9,245.13	9,377.41	9,468.05
B	EQUITY AND LIABILITIES			
1	Equity			
(a)	Equity share capital	850.49	850.49	850.49
(b)	Other equity	2,769.91	2,887.93	2,722.56
	Equity attributable to owner	3,620.40	3,738.42	3,573.05
	Non Controlling Interest	7.92	8.04	7.68
	Total Equity	3,628.32	3,746.46	3,580.73
2	Liabilities			
(I)	Non-current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	1,775.14	1,848.87	2,158.33
(b)	Provisions	28.91	23.06	28.91
(c)	Deferred tax liabilities (Net)	71.19	67.53	71.19
(d)	Other non - current liabilities		-	-
(II)	Current liabilities			
(a)	Financial liabilities			
(i)	Borrowings	2,213.09	1,225.52	1,568.51
(ii)	Trade payables	371.95	975.24	725.84
(iii)	Other current financial liabilities	1,040.93	1,276.71	1,205.36
(b)	Other current liabilities	113.07	211.90	125.43
(c)	Short-term provisions	2.53	2.12	3.75
	Total Liability	5,616.81	5,630.95	5,887.32
	TOTAL EQUITY AND LIABILITIES	9,245.13	9,377.41	9,468.05

By Order of the Board
For Parnax Lab Limited

Prakash M Shah
Whole Time Director & CEO
DIN : 00440980



Mumbai
Date : 14-11-2019

PARNAX LAB LIMITED
Unaudited Consolidated Cash Flow Statement

Particulars	(Rs. in Lakhs)	
	For the period ended 30th September 2019	For the year ended 31st March 2019
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit/(Loss) before tax	43.18	461.99
Adjustments for		
Depreciation	-	-
Finance Cost	212.97	382.35
Loss on sale of Property, plant & equipments	239.86	388.76
Sundry Balances written off	-	-
Diminution in value of Investments	0.52	7.17
Impairment of assets classified as held for disposal	-	-
Interest & Dividend income	-	-
	(1.12)	(7.97)
Operating Loss Before Working Capital Adjustments	495.42	1,232.30
Changes in Working Capital		
<u>Adjustments for (increase) / decrease in operating assets:</u>		
Inventories		
Trade receivables	(130.21)	(79.65)
Other assets (Financials and Non Financial assets)	(254.79)	(52.06)
	644.53	45.34
<u>Adjustments for increase / (decrease) in operating liabilities:</u>		
Trade payables	-	-
Other liabilities (Financials and Non Financial assets)	(263.06)	(41.76)
	(174.18)	(92.49)
Cash generated from operations	317.72	1,011.68
Direct Tax Paid (Refund) [Net]	58.25	140.10
Net cash flow from / (used in) operating activities (A)	259.47	871.58
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant & equipment	(254.99)	(1,132.06)
Proceeds from sale of fixed assets	-	7.54
Proceeds/(Purchase) from sale of Non Current Investments	-	1.86
Interest & Dividend income	1.12	7.97
Net cash flow from / (used in) investing activities (B)	(253.88)	(1,114.69)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from borrowings (net)	197.06	468.67
Finance Cost	(179.35)	(326.68)
Net cash flow from / (used in) financing activities (C)	17.70	141.99
Net increase (decrease) in cash and cash equivalents (A+B+C)	23.30	(101.12)
Cash and cash equivalents at the beginning of the year	(5.19)	95.93
Cash and cash equivalents at the end of the year	18.11	(5.19)

Mumbai
Date : 14-11-2019



By Order of the Board
For Parnax Lab Limited

(Signature)

Prakash M Shah
Whole Time Director & CEO
DIN : 00440980